Understanding treatments for gout

American Journal of Managed Care

Volumn 11, Issue SUPPL. 15, 2005, Pages

  Cannella, Amy C ^a   Mikuls, Ted R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMPICILLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; DIURETIC AGENT; ESTROGEN; FEBUXOSTAT; FENOFIBRATE; INDOMETACIN; LOSARTAN; METHYLPREDNISOLONE SODIUM SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PREDNISONE; PROBENECID; RASBURICASE; SULFINPYRAZONE; URATE OXIDASE; URIC ACID; URICOSURIC AGENT;

ABDOMINAL PAIN; ANAPHYLAXIS; COMORBIDITY; CORONARY ARTERY DISEASE; DIARRHEA; EOSINOPHILIA; FEVER; GASTROINTESTINAL TOXICITY; GOUT; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; LIFESTYLE; LIVER DYSFUNCTION; NAUSEA; NEUROMUSCULAR DISEASE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PURINE METABOLISM; RASH; REVIEW; RHEUMATIC DISEASE; TISSUE NECROSIS; URIC ACID STONE; VASCULITIS; VOMITING; WEIGHT REDUCTION;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; BEHAVIOR THERAPY; CHRONIC DISEASE; COLCHICINE; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH BEHAVIOR; HUMANS; HYPERURICEMIA; MALE; PRACTICE GUIDELINES; PURINES; RISK FACTORS; URIC ACID;

EID: 28344447925     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Poor G, Mituszova M. History, classification and epidemiology of crystal-related arthropathies. In: Hochberg MC, et al, eds. Rheumatology. Vol 2. New York, NY: Mosby; 2003:1893-1901.
2. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004;50:2400-2414.
3. Terkeltaub RA. Gout and mechanisms of crystal induced inflammation. Curr Opin Rheumatol. 1993;5:510-516.
4. McLean L. The pathogenesis of gout. In: Hochberg MC, et al, eds. Rheumatology. Vol 2. New York, NY: Mosby; 2003:1903-1918.
5. Sorensen LB, Levinson DJ. Origin and extrarenal elimination of uric acid in man. Nephron. 1975;14:7-20.
6. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG. Uric acid transport. Curr Opin Nephrol Hypertens. 2003;12:511-516.
7. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-452.
8. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29:1350-1355.
9. Wortmann RL Gout and hyperuricemia. Curr Opin Rheumatol. 2002;14:281-286.
10. Waller PC, Rasmay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens. 1989;3:457-461.
11. Terkeltaub R. Clinical practice. Gout. N Engl J Med. 2003;349:1647-1655.
12. Lin K, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045-1050.
13. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.
14. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-3007.
15. Myers AR, Epstein FH, Dodge HJ, Mikkelsen WM. The relationship of serum uric acid to risk factors in coronary heart disease. Am J Med. 1968;45:520-528.
16. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-451.
17. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539-543.
18. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Cans RO. Renal handling of urate and sodium during acute physiological hyperinsulineameia in healthy subjects. Clin Sci (Lond). 1997;92:51-58.
19. Muscelli E, Natali A, Bianchi S. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746-752.
20. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. JAMA. 1991;266:3008-3011.
21. Baker J, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-826.
22. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-1103.
23. Sharpe CR. A case-control study of alcohol consumption and drinking behaviour in patients with acute gout. Can Med Assoc J. 1984;131:563-567.
24. Rodnan G. The pathogenesis of aldermanic gout: procatarctic role of fluctuations in serum urate concentration in gouty arthritis provoked by feast and alcohol. Abstract. Arthritis Rheum. 1980;23(suppl):737.
25. Drum DE, Goldman PA, Jankowski CB. Elevation of serum uric acid as a clue to alcohol abuse. Arch Intern Med. 1981;141:477-479.
26. Eastmond CJ, Carton M, Robns S, Riddoch S. The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol. 1995;34:756-759.
27. Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med. 1982;307:1598-1602.
28. Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking and its effect on uric acid. Br J Rheumatol. 1984;23:203-209.
29. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H. Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol. 2000;27:1708-1712.
30. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indication of renal vascular involvement. Ann Intern Med. 1980;93:817-821.
31. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron. 1991;59:364-368.
32. Marcen R, Gellego N, Orofino L, et al. Influence of cyclosporine A (CyA) on renal handling of urate. Transpl Int. 1992;5(suppl 1):S81-S83.
33. Fam AG. Gout in the elderly: clinical presentation and treatment. Drugs Aging. 1998;13:229-243.
34. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48:1153-1158.
35. Currie WJ. Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis. 1979;38:101-106.
36. Becker M. Etiology and management of gout. 2005, UpToDate online 13.2.
37. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64:2399-2416.
38. Allison MC, Howatson AG, Torrance CI, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749-754.
39. Sandler DP, Burr IFR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991;115:165-172.
40. Porter R, Roussea G. Gout: The Patrician Malady. New Haven, Conn: Yale University Press; 1998.
41. Paulus HE, Schlossetein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy in intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-614.
42. Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy-classical indications and new therapeutic uses. Eur J Med Res. 2001;6:150-160.
43. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine. J Emerg Med. 2002;22:385-387.
44. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol. 1994;21:1325-1327.
45. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19:329-336.
46. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother. 2001;35:365-368.
47. Mikdashi JA, Hochberg MC, Moy EM, White B, Handwerger BS. Single-dose patenteral ACTH in the treatment of acute gouty arthritis: a high benefit to toxicity ratio. Abstract. Arthritis Rheum. 1994;37:S428.
48. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum. 1988;30:803-805.
49. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol. 1995;22:1621-1623.
50. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28:577-580.
51. Fam AG, Dunne SM, Iazzerta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44:231-238.
52. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
53. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol. 2005;17:319-324.
54. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916-923.
55. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 1993;250:455-460.
56. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother. 2003;37:1047-1054.
57. Goldman SC. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies. Expert Rev Anticancer Ther. 2003;3:429-433.
58. Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards antiuricase serum and high enzymatic activity. Enzyme. 1981;26:49-53.
59. Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002;29:1942-1949.
60. Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50:937-943.
61. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-2432.
62. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrol lees with gout: a restrospective analysis of administrative claims. J Rheumatol. 2004;31:1575-1581.
63. Loebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis. 1974;33:304-307.
64. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989;16:1246-1248.